Expression Patterns of Coagulation Factor XIII Subunit A on Leukemic Lymphoblasts Correlate with Clinical Outcome and Genetic Subtypes in Childhood B-cell Progenitor Acute Lymphoblastic Leukemia.
B-cell progenitor
Factor XIII subunit A
acute lymphoblastic leukemia
children
genetic risk categories
middle-income countries
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Aug 2020
13 Aug 2020
Historique:
received:
20
06
2020
revised:
03
08
2020
accepted:
10
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
Based on previous retrospective results, we investigated the association of coagulation FXIII subunit A (FXIII-A) expression pattern on survival and correlations with known prognostic factors of B-cell progenitor (BCP) childhood acute lymphoblastic leukemia (ALL) as a pilot study of the prospective multi-center BFM ALL-IC 2009 clinical trial. The study included four national centers ( Three different patterns of FXIII-A expression were observed: negative (<20%), dim (20-79%), and bright (≥80%). The FXIII-A dim expression group had significantly higher 5-year event-free survival (EFS) (93%) than the FXIII-A negative (70%) and FXIII-A bright (61%) groups. Distribution of intermediate genetic risk categories and the "B-other" genetic subgroup differed significantly between the FXIII-A positive and negative groups. Multivariate logistic regression confirmed independent association between the FXIII-A negative expression characteristics and the prevalence of intermediate genetic risk group. FXIII-A negativity is associated with dismal survival in children with BCP-ALL and is an indicator for the presence of unfavorable genetic alterations.
Sections du résumé
BACKGROUND
BACKGROUND
Based on previous retrospective results, we investigated the association of coagulation FXIII subunit A (FXIII-A) expression pattern on survival and correlations with known prognostic factors of B-cell progenitor (BCP) childhood acute lymphoblastic leukemia (ALL) as a pilot study of the prospective multi-center BFM ALL-IC 2009 clinical trial.
METHODS
METHODS
The study included four national centers (
RESULTS
RESULTS
Three different patterns of FXIII-A expression were observed: negative (<20%), dim (20-79%), and bright (≥80%). The FXIII-A dim expression group had significantly higher 5-year event-free survival (EFS) (93%) than the FXIII-A negative (70%) and FXIII-A bright (61%) groups. Distribution of intermediate genetic risk categories and the "B-other" genetic subgroup differed significantly between the FXIII-A positive and negative groups. Multivariate logistic regression confirmed independent association between the FXIII-A negative expression characteristics and the prevalence of intermediate genetic risk group.
CONCLUSIONS
CONCLUSIONS
FXIII-A negativity is associated with dismal survival in children with BCP-ALL and is an indicator for the presence of unfavorable genetic alterations.
Identifiants
pubmed: 32823516
pii: cancers12082264
doi: 10.3390/cancers12082264
pmc: PMC7463512
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Hungarian Science Foundation
ID : K108885
Organisme : Polish National Center for Research and Development
ID : STRATEGMED3/304586/5/NVBR/2017
Références
Leukemia. 1995 Oct;9(10):1783-6
pubmed: 7564526
Pediatr Blood Cancer. 2014 May;61(5):803-9
pubmed: 24376115
Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):202-205
pubmed: 27299191
N Engl J Med. 1998 Jun 4;338(23):1663-71
pubmed: 9614257
J Immunol Methods. 2019 Dec;475:112429
pubmed: 29530508
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Lancet. 2013 Jun 1;381(9881):1943-55
pubmed: 23523389
Pathol Res Pract. 2019 Feb;215(2):265-271
pubmed: 30466764
Front Oncol. 2019 Oct 25;9:1063
pubmed: 31709175
Blood. 2019 May 23;133(21):2305-2319
pubmed: 30814062
Thromb Haemost. 2015 Apr;113(4):686-97
pubmed: 25652913
Thromb Haemost. 2006 Aug;96(2):176-82
pubmed: 16894461
Pediatr Dev Pathol. 2011 Nov-Dec;14(6):480-4
pubmed: 21793710
Front Oncol. 2020 Jun 30;10:923
pubmed: 32695667
Leukemia. 2015 Nov;29(11):2154-61
pubmed: 26050650
Cytometry B Clin Cytom. 2018 Jan;94(1):82-93
pubmed: 28187514
J Cutan Pathol. 1989 Oct;16(5):266-71
pubmed: 2574200
Pediatr Blood Cancer. 2010 Jan;54(1):62-70
pubmed: 19760767
J Dermatol Sci. 1997 Nov;16(1):52-8
pubmed: 9438908
Cytometry B Clin Cytom. 2012 Jul;82(4):209-16
pubmed: 22434605
PLoS One. 2013 Sep 09;8(9):e74562
pubmed: 24040285
Pathol Res Pract. 2012 Aug 15;208(8):493-6
pubmed: 22784469
Br J Haematol. 2017 Aug;178(4):583-587
pubmed: 28439887
Blood. 2018 Mar 22;131(12):1350-1359
pubmed: 29284596
Physiol Rev. 2011 Jul;91(3):931-72
pubmed: 21742792
J Clin Oncol. 2013 Jul 20;31(21):2736-42
pubmed: 23775972
Blood. 2017 Jan 19;129(3):347-357
pubmed: 27903527
Blood. 1994 Nov 1;84(9):3122-33
pubmed: 7949185
Biomed Res Int. 2017;2017:3571861
pubmed: 28894750
Blood. 2013 Jun 20;121(25):e149-59
pubmed: 23649467
Leuk Lymphoma. 2017 Feb;58(2):333-342
pubmed: 27339065
Hum Pathol. 2016 Sep;55:44-50
pubmed: 27137987
Haematologica. 2016 Apr;101(4):407-16
pubmed: 27033238
J Adv Pract Oncol. 2016 Jan-Feb;7(1):91-100
pubmed: 27713848
J Cell Sci. 1996 Nov;109 ( Pt 11):2727-35
pubmed: 8937990
Pediatr Blood Cancer. 2017 Dec;64 Suppl 5:
pubmed: 29297619
Cytometry A. 2008 Mar;73(3):194-201
pubmed: 18000871
J Dermatol Sci. 1991 Jan;2(1):50-4
pubmed: 1675869
Pathol Oncol Res. 2018 Apr;24(2):345-352
pubmed: 28523449
J Immunol Methods. 2001 Dec 1;258(1-2):127-35
pubmed: 11684129
J Clin Oncol. 2014 Jan 20;32(3):174-84
pubmed: 24344215
Am J Dermatopathol. 2007 Apr;29(2):197-200
pubmed: 17414448
J Clin Oncol. 2014 Jan 20;32(3):169-70
pubmed: 24344213
Blood. 2014 Aug 28;124(9):1434-44
pubmed: 24957142
J Clin Oncol. 2017 Mar 20;35(9):975-983
pubmed: 28297628
Leukemia. 2013 Feb;27(2):295-304
pubmed: 22699455
Klin Padiatr. 1981 May;193(3):145-54
pubmed: 6943387